Stock & Company Details
TG Therapeutics Inc $TGTX
Price:
N/A
N/A
153M
$8.2B
52 Week High:
N/A
10 Day Average Volume:
N/A
19.43
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
TGTX technical indicators
Latest TG Therapeutics Inc (TGTX) indicator readings as of 2026-10-09.
TGTX's 14-day RSI is 52.5, in neutral territory. At $55.37 it is trading 32.2% above its 200-day moving average of $41.89, and above its 50-day average of $53.59. Price sits in the middle of its Bollinger Bands ($51.88 to $58.75). ADX reads 19.2, indicating a range-bound market rather than a trend.
TGTX backtested strategy results
How 4 rule-based strategies performed on TG Therapeutics Inc (TGTX) over recent history, last backtested 2026-09-09. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | -52.2% | 23% | 13 | -84.5% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | +207.2% | 40% | 30 | -46.2% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | +234.3% | 53% | 30 | -36.2% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | +4.7% | 49% | 35 | -78.1% |
Overview
TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Finance Bot
Ask your questions
Start by typing a question below.
